Sangamo Therapeutics Announces Pfizer's Phase 3 Trial Of Giroctocogene Fitelparvovec Meets Primary And Key Secondary Objectives; Eligible For Up To $220M In Milestone Payments And 14%-20% Royalties If Approved And Commercialized
Portfolio Pulse from Benzinga Newsdesk
Sangamo Therapeutics announced that Pfizer's Phase 3 trial of Giroctocogene Fitelparvovec met its primary and key secondary objectives. Sangamo is eligible for up to $220 million in milestone payments and 14%-20% royalties if the therapy is approved and commercialized.
July 24, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's successful Phase 3 trial of Giroctocogene Fitelparvovec could lead to new revenue streams through commercialization, benefiting from Sangamo's gene therapy technology.
The successful Phase 3 trial indicates potential new revenue streams for Pfizer through the commercialization of Giroctocogene Fitelparvovec, positively impacting PFE's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 80
POSITIVE IMPACT
Sangamo Therapeutics could receive up to $220 million in milestone payments and 14%-20% royalties from Pfizer's successful Phase 3 trial of Giroctocogene Fitelparvovec.
The successful Phase 3 trial by Pfizer significantly boosts the potential revenue for Sangamo Therapeutics through milestone payments and royalties, likely leading to a positive short-term impact on SGMO's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100